PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non–Small Cell Lung Cancer Treated with Curative Radiotherapy

Bourbonne et al. (Thu,) studied this question.

www.synapsesocial.com/papers/68e7907ab6db64358770192f — DOI: https://doi.org/10.2967/jnumed.123.266749

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non–small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial· 2011 · 754 citations
2. Role of <i>KEAP1</i> / <i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance· 2016 · 360 citations
3. Computational Radiomics System to Decode the Radiographic Phenotype· 2017 · 6,395 citations
4. The Role of Nrf2 Activity in Cancer Development and Progression· 2019 · 287 citations
5. A radiogenomic dataset of non-small cell lung cancer· 2018 · 312 citations